Nuclear medicine at the Royalcare Institute of Oncology harnesses the power of safe, traceable radioactive tracers to visualize bodily functions and treat select cancers at the cellular level. Unlike standard imaging, nuclear medicine shows how organs and tissues work, enabling early detection, accurate staging and targeted therapies. Our expert team collaborates with other oncology specialties to deliver precise and personalized care.
Number of Specialists
No of patients
No of surgeries done
Our nuclear medicine department also provides targeted radionuclide therapies, including:
At the Radiation Oncology department, we treat a wide range of cancers using tailored radiotherapy techniques:
Cancer staging and restaging using PET/CT and SPECT imaging.
Thyroid disorders and cancer evaluation with thyroid and whole body I-131 scans.
Bone metastases and painful skeletal lesions are detected and treated with bone scans and palliation therapies.
Cardiac function assessment via MPI and MUGA studies.
Liver, lung, kidney, GI and neurological functional disorders are evaluated through specialized imaging protocols.
Nuclear medicine uses small amounts of radioactive tracers to assess how organs function at the cellular level, unlike standard imaging that shows only structure.
Yes, all tracer doses are carefully calculated to provide accurate information with minimal radiation exposure.
Some scans require fasting or hydration guidelines before the test; specific instructions are provided prior to your appointment.
Yes, therapies such as I-131 thyroid therapy, radionuclide pain palliation and PSMA/PRRT treatments target cancer cells using radioactive agents.
Scan durations vary based on the procedure, typically ranging from 30 minutes to a few hours including tracer uptake time.